Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma

NCT05433142 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT05433142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05433142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma
Lead sponsor
Xencor, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 13, 2022
Completion date
December 31, 2028
Enrollment
307 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma